ME02118B - Nova kompozicija za tretman esencijalne trombocitemije - Google Patents

Nova kompozicija za tretman esencijalne trombocitemije

Info

Publication number
ME02118B
ME02118B MEP-2015-61A MEP6115A ME02118B ME 02118 B ME02118 B ME 02118B ME P6115 A MEP6115 A ME P6115A ME 02118 B ME02118 B ME 02118B
Authority
ME
Montenegro
Prior art keywords
treatment
novel composition
essential thrombocythemia
thrombocythemia
essential
Prior art date
Application number
MEP-2015-61A
Other languages
English (en)
Inventor
Rudolf Widmann
Georg Strieder
Original Assignee
Aop Orphan Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42732455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02118(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aop Orphan Pharmaceuticals Ag filed Critical Aop Orphan Pharmaceuticals Ag
Publication of ME02118B publication Critical patent/ME02118B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Paints Or Removers (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MEP-2015-61A 2010-03-25 2011-03-25 Nova kompozicija za tretman esencijalne trombocitemije ME02118B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10157772 2010-03-25
EP11710202.0A EP2549983B1 (en) 2010-03-25 2011-03-25 Novel composition for treatment of essential thrombocythemia
PCT/EP2011/054628 WO2011117391A2 (en) 2010-03-25 2011-03-25 Novel composition for treatment of essential thrombocythemia

Publications (1)

Publication Number Publication Date
ME02118B true ME02118B (me) 2015-10-20

Family

ID=42732455

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2015-61A ME02118B (me) 2010-03-25 2011-03-25 Nova kompozicija za tretman esencijalne trombocitemije

Country Status (23)

Country Link
US (4) US20130028945A1 (me)
EP (1) EP2549983B1 (me)
JP (1) JP5836357B2 (me)
AU (1) AU2011231557B2 (me)
BR (1) BR112012024239A2 (me)
CA (1) CA2794237C (me)
CY (1) CY1116396T1 (me)
DK (1) DK2549983T3 (me)
EA (1) EA027576B1 (me)
ES (1) ES2535480T3 (me)
HR (1) HRP20150410T1 (me)
IL (1) IL222072A (me)
ME (1) ME02118B (me)
MX (1) MX2012011051A (me)
NZ (1) NZ602366A (me)
PL (1) PL2549983T3 (me)
PT (1) PT2549983E (me)
RS (1) RS53960B1 (me)
SG (1) SG184227A1 (me)
SI (1) SI2549983T1 (me)
SM (1) SMT201500119B (me)
UA (1) UA110933C2 (me)
WO (1) WO2011117391A2 (me)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA110933C2 (uk) * 2010-03-25 2016-03-10 Аоп Орфан Фармацойтікальс Аг Композиція для лікування есенціальної тромбоцитемії
WO2016102952A1 (en) 2014-12-22 2016-06-30 Aluztra Bio Ltd Prevention and treatment of metastatic disease in thrombocytotic cancer patients
EP4183430A1 (en) 2021-11-18 2023-05-24 Koninklijke Philips N.V. Sensor arrangement for a breast pump device and breast pump device using the sensor arrangement

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AU2003231777C1 (en) * 2002-04-29 2009-10-29 Supernus Pharmaceuticals, Inc. Pharmaceutical formulations with improved bioavailability
US7993654B2 (en) * 2002-12-23 2011-08-09 Beiersdorf Ag Self-adhesive polymer matrix containing sea algae extract
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
CN101588794A (zh) * 2007-01-25 2009-11-25 万能药生物有限公司 调节释放药物组合物及其制备方法
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
AT10562U3 (de) * 2008-12-05 2010-01-15 Aop Orphan Pharmaceuticals Ag Neuartige zusammensetzung zur behandlung einer essenziellen thrombozytämie
US8465770B2 (en) * 2008-12-24 2013-06-18 Synthon Bv Low dose controlled release tablet
UA110933C2 (uk) * 2010-03-25 2016-03-10 Аоп Орфан Фармацойтікальс Аг Композиція для лікування есенціальної тромбоцитемії

Also Published As

Publication number Publication date
ES2535480T3 (es) 2015-05-12
PL2549983T3 (pl) 2015-08-31
SI2549983T1 (sl) 2015-06-30
RS53960B1 (en) 2015-08-31
WO2011117391A2 (en) 2011-09-29
US20180028538A1 (en) 2018-02-01
IL222072A (en) 2017-12-31
US20150086637A1 (en) 2015-03-26
NZ602366A (en) 2014-08-29
JP2013523616A (ja) 2013-06-17
HRP20150410T1 (hr) 2015-06-05
EA027576B1 (ru) 2017-08-31
SMT201500119B (it) 2015-07-09
EP2549983B1 (en) 2015-03-04
EA201201329A1 (ru) 2013-02-28
AU2011231557B2 (en) 2016-05-26
CA2794237A1 (en) 2011-09-29
SG184227A1 (en) 2012-10-30
MX2012011051A (es) 2013-01-29
UA110933C2 (uk) 2016-03-10
US9782413B2 (en) 2017-10-10
US20130028945A1 (en) 2013-01-31
PT2549983E (pt) 2015-06-17
CA2794237C (en) 2017-09-26
BR112012024239A2 (pt) 2016-07-12
WO2011117391A3 (en) 2012-01-19
CY1116396T1 (el) 2017-02-08
JP5836357B2 (ja) 2015-12-24
US20170035768A1 (en) 2017-02-09
EP2549983A2 (en) 2013-01-30
AU2011231557A1 (en) 2012-10-04
DK2549983T3 (da) 2015-06-01

Similar Documents

Publication Publication Date Title
EP2554175A4 (en) COMPOSITION FOR THE TREATMENT OF A DESIRED PART
IL229830B (en) Novel compinds as modulatord of gpr-119
ZA201304280B (en) Treatment of jak2-mediated conditions
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
PL2609120T3 (pl) Ulepszony sposób wytwarzania sugammadeksu
PT3023788T (pt) Composições de neoantigénios específicos de tumor para utilização no tratamento de tumores
HK1178465A1 (en) Composition for improving condition of skin
EP2542515A4 (en) PHOTOCATALYST MATERIAL COMPOSITION
EP2663576A4 (en) NEW WNT COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF SUCH COMPOSITIONS
IL256026B (en) Treatment methods
IL224381B (en) Application of b-functionalized dihydroxy-chlorins for pdt
HUE047320T2 (hu) Terméketlenség kezelésére szolgáló kompozíció
HRP20130647T1 (en) Novel composition for treatment of essential thrombocythemia
IL222072A (en) Composition for the treatment of primary thrombocythemia
PL2460509T3 (pl) Kompozycja do leczenia brodawek
PT2603319E (pt) Processo para a preparação de uretanos
HK1206633A1 (en) Composition for treatment of warts
GB201010638D0 (en) Composition for treatment of skin
HK1160777A1 (en) Novel use of neohesperidoside
IL222903A0 (en) Composition of small molecule therapeutices
GB201012310D0 (en) Composition for the treatment of botulism